http://orcid.org/0000-0002-0532-8991
Citations (46)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Wenbing Zhang, Jian Ding, Wenhai Wang, Duo Wang, Yinping Pan & Dexin Xu. (2023) Status and Future Directions of Therapeutics and Prognosis of Cardiac Amyloidosis. Therapeutics and Clinical Risk Management 19, pages 581-597.
Read now
Read now
Felix J. Tsai, Luke T. Nelson, Gabriel M. Kline, Marcus Jäger, John L. Berk, Yoshiki Sekijima, Evan T. Powers & Jeffery W. Kelly. (2023) Characterising diflunisal as a transthyretin kinetic stabilizer at relevant concentrations in human plasma using subunit exchange. Amyloid 30:2, pages 220-224.
Read now
Read now
Omar K. Siddiqi, Yuliya Y. Mints, John L. Berk, Lawreen Connors, Gheorghe Doros, Deepa M. Gopal, Shivangi Kataria, Graham Lohrmann, Alexandra R. Pipilas & Frederick L. Ruberg. (2022) Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston University Amyloidosis Center experience. Amyloid 29:2, pages 71-78.
Read now
Read now
Bennett Di Giovanni, Dakota Gustafson & Diego Hernan Delgado. (2019) Amyloid transthyretin cardiac amyloidosis: diagnosis and management. Expert Review of Cardiovascular Therapy 17:9, pages 673-681.
Read now
Read now
Articles from other publishers (42)
Michael A. Smith & Neil G. Feinglass. (2024) Perioperative implications of amyloidosis and amyloid cardiomyopathy: A review for anesthesiologists. Journal of Clinical Anesthesia 92, pages 111271.
Crossref
Crossref
Juan Zhou, Yanfang LiJing GengHong ZhouLian LiuXiaochun Peng. (2023) Recent Progress in the Development and Clinical Application of New Drugs for Transthyretin Cardiac Amyloidosis. Journal of Cardiovascular Pharmacology 82:6, pages 427-437.
Crossref
Crossref
Dulce Brito, Fabiano Castro Albrecht, Diego Perez de Arenaza, Nicole Bart, Nathan Better, Isabel Carvajal-Juarez, Isabel Conceição, Thibaud Damy, Sharmila Dorbala, Jean-Christophe Fidalgo, Pablo Garcia-Pavia, Junbo Ge, Julian D. Gillmore, Jacek Grzybowski, Laura Obici, Daniel Piñero, Claudio Rapezzi, Mitsuharu Ueda & Fausto J. Pinto. (2023) World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). Global Heart 18:1.
Crossref
Crossref
Andy Y. Wang, Jainith Patel, Matthew Kanter, Michelle Olmos, Mathew S. Maurer, Ellen D. McPhail, Ayan R. Patel, Knarik Arkun, James Kryzanski & Ron I. Riesenburger. (2023) The Emerging Significance of Amyloid Deposits in the Ligamentum Flavum of Spinal Stenosis Patients: A Review. World Neurosurgery 177, pages 88-97.
Crossref
Crossref
Liana Chan, Mihyun Park, Hong Lee, Siyang Chaili, Yan Xiong, Arnold Bayer, Richard Proctor & Michael Yeaman. (2023) Diflunisal Attenuates Virulence Factor Gene Regulation and Phenotypes in Staphylococcus aureus. Antibiotics 12:5, pages 902.
Crossref
Crossref
Paolo Morfino, Alberto Aimo, Giuseppe Vergaro, Chiara Sanguinetti, Vincenzo Castiglione, Maria Franzini, Marco Alfonso Perrone & Michele Emdin. (2023) Transthyretin Stabilizers and Seeding Inhibitors as Therapies for Amyloid Transthyretin Cardiomyopathy. Pharmaceutics 15:4, pages 1129.
Crossref
Crossref
Andrea Frustaci, Romina Verardo, Matteo Russo, Marina Caldarulo, Maria Alfarano, Nicola Galea, Fabio Miraldi & Cristina Chimenti. (2023) Infiltration of Conduction Tissue Is a Major Cause of Electrical Instability in Cardiac Amyloidosis. Journal of Clinical Medicine 12:5, pages 1798.
Crossref
Crossref
Mohamed Toufic El Hussein & Daniel Favell. (2023) Pharmacological Management of Transthyretin Cardiac Amyloidosis. The Journal for Nurse Practitioners 19:2, pages 104480.
Crossref
Crossref
Mario Nuvolone, Maria Girelli & Giampaolo Merlini. (2022) Oral Therapy for the Treatment of Transthyretin-Related Amyloid Cardiomyopathy. International Journal of Molecular Sciences 23:24, pages 16145.
Crossref
Crossref
Zaida L. Almeida & Rui M. M. Brito. (2022) Amyloid Disassembly: What Can We Learn from Chaperones?. Biomedicines 10:12, pages 3276.
Crossref
Crossref
Mathew S. Maurer. (2022) Overview of Current and Emerging Therapies for Amyloid Transthyretin Cardiomyopathy. The American Journal of Cardiology 185, pages S23-S34.
Crossref
Crossref
Pranav Chandrashekar, Anish K. Desai & Barry H. Trachtenberg. (2021) Targeted treatments of AL and ATTR amyloidosis. Heart Failure Reviews 27:5, pages 1587-1603.
Crossref
Crossref
Jose N. Nativi-Nicolau, Chafic Karam, Sami Khella & Mathew S. Maurer. (2021) Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness. Heart Failure Reviews 27:3, pages 785-793.
Crossref
Crossref
Velina Nedkova-Hristova, Carmen Baliellas, José González-Costello, Laura Lladó, Emma González-Vilatarsana, Valentina Vélez-Santamaría & Carlos Casasnovas. (2022) Treatment With Diflunisal in Domino Liver Transplant Recipients With Acquired Amyloid Neuropathy. Transplant International 35.
Crossref
Crossref
Michel Ibrahim, Garly Rushler Saint Croix, Spencer Lacy, Michael Fattouh, Maria Irene Barillas-Lara, Leili Behrooz & Olivia Mechanic. (2021) The use of diflunisal for transthyretin cardiac amyloidosis: a review. Heart Failure Reviews 27:2, pages 517-524.
Crossref
Crossref
Emily Plumadore, Lindsay Lombardo & Katherine P Cabral. (2022) Pharmacotherapy review: Emerging treatment modalities in transthyretin cardiac amyloidosis. American Journal of Health-System Pharmacy 79:2, pages 52-62.
Crossref
Crossref
Monica Alcantara, Michelle M. Mezei, Steven K. Baker, Ari Breiner, Priya Dhawan, Amanda Fiander, Nowell M. Fine, Christopher Hahn, Hans D. Katzberg, Shahin Khayambashi, Rami Massie, Genevieve Matte, Brendan Putko, Zaeem Siddiqi, Diego Delgado & Vera Bril. (2021) Canadian Guidelines for Hereditary Transthyretin Amyloidosis Polyneuropathy Management. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 49:1, pages 7-18.
Crossref
Crossref
Michele Lioncino, Emanuele Monda, Giuseppe Palmiero, Martina Caiazza, Erica Vetrano, Marta Rubino, Augusto Esposito, Gemma Salerno, Francesca Dongiglio, Barbara D’Onofrio, Federica Verrillo, Giuseppe Cerciello, Fiore Manganelli, Giuseppe Pacileo, Eduardo Bossone, Paolo Golino, Paolo Calabrò & Giuseppe Limongelli. (2022) Cardiovascular Involvement in Transthyretin Cardiac Amyloidosis. Heart Failure Clinics 18:1, pages 73-87.
Crossref
Crossref
Alberta L. Warner. (2021) Advances in the treatment of transthyretin cardiac amyloidosis: Current and emerging therapies. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 41:12, pages 1081-1091.
Crossref
Crossref
Petr Snetkov, Svetlana Morozkina, Roman Olekhnovich & Mayya Uspenskaya. (2021) Diflunisal Targeted Delivery Systems: A Review. Materials 14:21, pages 6687.
Crossref
Crossref
Csilla Andrea Eötvös, Giorgia Pastiu, Iulia Zehan, Cerasela Goidescu, Roxana Chiorescu, Roxana Lazar, Florina Frîngu, Raluca Tomoaia, Monica Pop, Adrian Molnar, Sorin Pop & Dan Blendea. 2021. Cardiomyopathy - Disease of the Heart Muscle. Cardiomyopathy - Disease of the Heart Muscle.
Robert Daniel Adam, Daniel Coriu, Andreea Jercan, Sorina Bădeliţă, Bogdan A. Popescu, Thibaud Damy & Ruxandra Jurcuţ. (2021) Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature. ESC Heart Failure 8:4, pages 2380-2396.
Crossref
Crossref
Vasiliki Bistola, John Parissis, Emmanouil Foukarakis, Pipitsa N. Valsamaki, Aris Anastasakis, Georgios Koutsis, Georgios Efthimiadis & Efstathios Kastritis. (2021) Practical recommendations for the diagnosis and management of transthyretin cardiac amyloidosis. Heart Failure Reviews 26:4, pages 861-879.
Crossref
Crossref
Lily K. Stern & Michelle M. Kittleson. (2021) Updates in Cardiac Amyloidosis Diagnosis and Treatment. Current Oncology Reports 23:4.
Crossref
Crossref
Shan He, Xinyue He, Lei Liu, Wenbo Zhang, Lanlan Yu, Zhun Deng, Zhang Feiyi, Shanshan Mo, Yue Fan, Xinyue Zhao, Lun Wang, Chenxuan Wang & Shuyang Zhang. (2021) The Structural Understanding of Transthyretin Misfolding and the Inspired Drug Approaches for the Treatment of Heart Failure Associated With Transthyretin Amyloidosis. Frontiers in Pharmacology 12.
Crossref
Crossref
Jan M. Griffin & Mathew S. Maurer. (2021) Transthyretin cardiac amyloidosis: A treatable form of heart failure with a preserved ejection fraction. Trends in Cardiovascular Medicine 31:1, pages 59-66.
Crossref
Crossref
Evan T. Powers & Jeffery W. Kelly. 2021. Neurotherapeutics in the Era of Translational Medicine. Neurotherapeutics in the Era of Translational Medicine
65
103
.
Philip Haaf, Irene A. Burger, Michael J. Zellweger, Pankaj Garg & Cristina E. Popescu. 2021. Imaging of Inflammation and Infection in Cardiovascular Diseases. Imaging of Inflammation and Infection in Cardiovascular Diseases
37
69
.
Massimo Russo, Luca Gentile, Antonio Toscano, M’Hammed Aguennouz, Giuseppe Vita & Anna Mazzeo. (2020) Advances in Treatment of ATTRv Amyloidosis: State of the Art and Future Prospects. Brain Sciences 10:12, pages 952.
Crossref
Crossref
Gabriela Spencer-Bonilla, Kevin M. Alexander & Ronald M. Witteles. (2020) Advances in the Diagnosis and Management of Transthyretin Amyloid Cardiomyopathy. Current Treatment Options in Cardiovascular Medicine 22:11.
Crossref
Crossref
Catherine Teng, Pengyang Li, Ju Young Bae, Su Pan, Richard A. F. Dixon & Qi Liu. (2020) Diagnosis and treatment of transthyretin‐related amyloidosis cardiomyopathy. Clinical Cardiology 43:11, pages 1223-1231.
Crossref
Crossref
Graham Lohrmann, Alexandra Pipilas, Roberta Mussinelli, Deepa M. Gopal, John L. Berk, Lawreen H. Connors, Nirupama Vellanki, Jennifer Hellawell, Omar K. Siddiqi, Jonathan Fox, Mathew S. Maurer & Frederick L. Ruberg. (2020) Stabilization of Cardiac Function With Diflunisal in Transthyretin (ATTR) Cardiac Amyloidosis. Journal of Cardiac Failure 26:9, pages 753-759.
Crossref
Crossref
Michelle M. Kittleson, Mathew S. Maurer, Amrut V. Ambardekar, Renee P. Bullock-Palmer, Patricia P. Chang, Howard J. Eisen, Ajith P. Nair, Jose Nativi-Nicolau & Frederick L. Ruberg. (2020) Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. Circulation 142:1.
Crossref
Crossref
Ariane Vieira Scarlatelli Macedo, Pedro Vellosa Schwartzmann, Breno Moreno de Gusmão, Marcelo Dantas Tavares de Melo & Otávio Rizzi Coelho-Filho. (2020) Advances in the Treatment of Cardiac Amyloidosis. Current Treatment Options in Oncology 21:5.
Crossref
Crossref
Tahir Nazir & Mahmud Nuffati. (2020) Cardiac amyloidosis—an underdiagnosed cause of heart failure in the elderly. Journal of the Saudi Heart Association 32:1.
Crossref
Crossref
Nowell M. Fine, Margot K. Davis, Kim Anderson, Diego H. Delgado, Genevieve Giraldeau, Abhijat Kitchlu, Rami Massie, Jane Narayan, Elizabeth Swiggum, Christopher P. Venner, Anique Ducharme, Natalie J. Galant, Christopher Hahn, Jonathan G. Howlett, Lisa Mielniczuk, Marie-Claude Parent, Donna Reece, Virginie Royal, Mustafa Toma, Sean A. Virani & Shelley Zieroth. (2020) Canadian Cardiovascular Society/Canadian Heart Failure Society Joint Position Statement on the Evaluation and Management of Patients With Cardiac Amyloidosis. Canadian Journal of Cardiology 36:3, pages 322-334.
Crossref
Crossref
Eileen O’Meara, Michael McDonald, Michael Chan, Anique Ducharme, Justin A. Ezekowitz, Nadia Giannetti, Adam Grzeslo, George A. Heckman, Jonathan G. Howlett, Sheri L. Koshman, Serge Lepage, Lisa M. Mielniczuk, Gordon W. Moe, Elizabeth Swiggum, Mustafa Toma, Sean A. Virani, Shelley Zieroth, Sabe De, Sylvain Matteau, Marie-Claude Parent, Anita W. Asgar, Gideon Cohen, Nowell Fine, Margot Davis, Subodh Verma, David Cherney, Howard Abrams, Abdul Al-Hesayen, Alain Cohen-Solal, Michel D’Astous, Diego H. Delgado, Olivier Desplantie, Estrellita Estrella-Holder, Lee Green, Haissam Haddad, Karen Harkness, Adrian F. Hernandez, Simon Kouz, Marie-Hélène LeBlanc, Douglas Lee, Frederick A. Masoudi, Robert S. McKelvie, Miroslaw Rajda, Heather J. Ross & Bruce Sussex. (2020) CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis. Canadian Journal of Cardiology 36:2, pages 159-169.
Crossref
Crossref
Jonah RubinMathew S. Maurer. (2020) Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable. Annual Review of Medicine 71:1, pages 203-219.
Crossref
Crossref
Maximilian L. Müller, Javed Butler & Bettina Heidecker. (2020) Emerging therapies in transthyretin amyloidosis – a new wave of hope after years of stagnancy?. European Journal of Heart Failure 22:1, pages 39-53.
Crossref
Crossref
Kevin M. Alexander, Alessandro Evangelisti & Ronald M. Witteles. (2019) Emerging Therapies for Transthyretin Cardiac Amyloidosis. Current Treatment Options in Cardiovascular Medicine 21:8.
Crossref
Crossref
Frederick L. Ruberg, Martha Grogan, Mazen Hanna, Jeffery W. Kelly & Mathew S. Maurer. (2019) Transthyretin Amyloid Cardiomyopathy. Journal of the American College of Cardiology 73:22, pages 2872-2891.
Crossref
Crossref
. (2019) Diflunisal. Reactions Weekly 1736:1, pages 94-94.
Crossref
Crossref